WO2009027803A3 - Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy) - Google Patents

Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy) Download PDF

Info

Publication number
WO2009027803A3
WO2009027803A3 PCT/IB2008/002233 IB2008002233W WO2009027803A3 WO 2009027803 A3 WO2009027803 A3 WO 2009027803A3 IB 2008002233 W IB2008002233 W IB 2008002233W WO 2009027803 A3 WO2009027803 A3 WO 2009027803A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonyl
phenoxy
pyridine
tert
benzyl
Prior art date
Application number
PCT/IB2008/002233
Other languages
English (en)
Other versions
WO2009027803A2 (fr
Inventor
David Burns Damon
Joseph Francis Krzyzaniak
Original Assignee
Pfizer Prod Inc
David Burns Damon
Joseph Francis Krzyzaniak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, David Burns Damon, Joseph Francis Krzyzaniak filed Critical Pfizer Prod Inc
Publication of WO2009027803A2 publication Critical patent/WO2009027803A2/fr
Publication of WO2009027803A3 publication Critical patent/WO2009027803A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines polymorphes du composé acide acétique (3-(((4-tert-butyl-benzyl)-(pyridine- 3-sulfonyl)-amino)-méthyl)-phénoxy), ainsi que des procédés de préparation de celles-ci, des procédés d'utilisation de celles-ci et des compositions pharmaceutiques les contenant. L'invention concerne également des formes cristallines polymorphes sensiblement pures d'acide acétique (3- (((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)-phénoxy).
PCT/IB2008/002233 2007-08-29 2008-08-22 Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy) WO2009027803A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96877707P 2007-08-29 2007-08-29
US60/968,777 2007-08-29

Publications (2)

Publication Number Publication Date
WO2009027803A2 WO2009027803A2 (fr) 2009-03-05
WO2009027803A3 true WO2009027803A3 (fr) 2009-07-23

Family

ID=40351584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002233 WO2009027803A2 (fr) 2007-08-29 2008-08-22 Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy)

Country Status (1)

Country Link
WO (1) WO2009027803A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103270094B (zh) 2010-12-27 2015-04-01 陶氏环球技术有限责任公司 高强度挤塑型热塑性聚合物泡沫

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019300A1 (fr) * 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019300A1 (fr) * 1997-10-10 1999-04-22 Pfizer Inc. Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux

Also Published As

Publication number Publication date
WO2009027803A2 (fr) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2010067374A3 (fr) Polymorphes de dasatinib
WO2009053854A3 (fr) Polymorphes de dasatinib et leur procédé de préparation
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2010139981A3 (fr) Procédés d'élaboration de formes cristallines
WO2011141933A3 (fr) Procédé pour la préparation d'acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique et ses sels acceptables sur le plan pharmaceutique
PL2352721T3 (pl) Nowy sposób wytwarzania pochodnych aminokwasów
WO2008062478A3 (fr) Procédé perfectionné pour préparer du montélukast sodique pur par des intermédiaires purs ainsi que nouveaux sels d'amines
WO2009141718A3 (fr) Procédé de préparation d'analogues de la prostaglandine et de leurs intermédiaires
WO2008155615A3 (fr) Procédé perfectionné pour la préparation d'un antibiotique de la famille des céphalosporines
WO2009104021A3 (fr) Nouveaux polymorphes et procédés de préparation
WO2009095933A3 (fr) Procédé perfectionné et nouveau pour la préparation de bosentan
WO2009141091A8 (fr) Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production
WO2011024192A3 (fr) Nouveaux polymorphes du raltegravir
WO2010076810A3 (fr) Procédé d'élaboration de géfitinibe
WO2011087316A3 (fr) Procédé pour préparer des sels d'acide tétrazole-méthanesulfonique, et nouveau composé utilisé dans celui-ci
WO2009053446A3 (fr) Nouveaux intermédiaires de prégabaline et procédé de préparation desdits intermédiaires et de prégabaline
HRP20181437T1 (hr) Postupak proizvodnje (3s,3s') 4,4' disulfanedilbis (3-aminobutan-1-sulfonske kiseline)
WO2012030106A3 (fr) Procédé de production d'un composé intermédiaire pour la synthèse d'un médicament
WO2008092939A3 (fr) Procédé de préparation d'oméprazole optiquement pur
TW200740729A (en) Methods for preparing glutamic acid derivatives
WO2009062659A3 (fr) Polymorphes d'erdostéine énantiopure
WO2009116081A3 (fr) Procédé amélioré de préparation daprépitant
WO2009060297A3 (fr) Procédé perfectionné pour la préparation de la palipéridone et de ses intermédiaires
WO2011135586A3 (fr) Procédé de préparation de dérivés chiraux de bêta-amino carboxamide
WO2008104957A3 (fr) Nouvelles formes polymorphes d'hydrochlorure de milnacipran

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08806936

Country of ref document: EP

Kind code of ref document: A2